CD8A and neoplasm: On Day 4, compared with the control treatment, anti-PD-L1 treatment both with and without anti-VEGF treatment resulted in higher percentages of CD8+ T cells and GzmB+CD8+ T cells in tumor tissues in the HM-1 model (Fig. S1).